Skip to Main content Skip to Navigation
Journal articles

Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis.

Candice Trocmé 1 Hubert Marotte 2 Athan Baillet 3 Béatrice Pallot-Prades 4 Jérome Garin 5 Laurent Grange 3 Pierre Miossec 2 Jacques Tebib 2 François Berger 6 Michael Nissen 7 Robert Juvin 7 Françoise Morel 1 Philippe Gaudin 3, *
* Corresponding author
1 GREPI
TIMC [2011-2015] - Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 [2011-2015], Laboratoire d'enzymologie/DBPC
3 GREPI
TIMC [2011-2015] - Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 [2011-2015], Service de Rhumatologie
Abstract : OBJECTIVES: The use of biologicals such as infliximab has dramatically improved the treatment of rheumatoid arthritis (RA). However, factors predictive of therapeutic response need to be identified. A proteomic study was performed prior to infliximab therapy to identify a panel of candidate protein biomarkers of RA predictive of treatment response. METHODS: Plasma profiles of 60 patients with RA (28 non-responders (as defined by the American College of Rheumatology 20% improvement criteria (ACR20)) negative and 32 responders (ACR70 positive) to infliximab) were studied by surface enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS) technology on two types of arrays, an anion exchange array (SAX2) and a nickel affinity array (IMAC3-Ni). Biomarker characterisation was carried out using classical biochemical methods (purification by ammonium sulfate precipitation or metal affinity chromatography) and identification by matrix assisted laser desorption/ionisation time-of-flight (MALDI-TOF) MS analysis. RESULTS: Two distinct protein profiles were observed on both arrays and several proteins were differentially expressed in both patient populations. Five proteins at 3.86, 7.77, 7.97, 8.14 and 74.07 kDa were overexpressed in the non-responder group, whereas one at 28 kDa was increased in the responder population (sensitivity>56%, specificity>77.5%). Moreover, combination of several biomarkers improved the sensitivity and specificity of the detection of patient response to over 97%. The 28 kDa protein was characterised as apolipoprotein A-I and the 7.77 kDa biomarker was identified as platelet factor 4. CONCLUSIONS: Six plasma biomarkers are characterised, enabling the detection of patient response to infliximab with high sensitivity and specificity. Apolipoprotein A-1 was predictive of a good response to infliximab, whereas platelet factor 4 was associated with non-responders.
Complete list of metadatas

Cited literature [35 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00382264
Contributor : Jean-Paul Issartel <>
Submitted on : Tuesday, June 2, 2009 - 11:35:34 AM
Last modification on : Thursday, August 27, 2020 - 11:36:03 AM
Long-term archiving on: : Thursday, June 10, 2010 - 9:07:59 PM

Files

Trocme_ApolipoproteinA1.pdf
Files produced by the author(s)

Identifiers

Collections

IMAG | CNRS | CEA | U836 | UGA | TIMC-IMAG | HCL | HEH

Citation

Candice Trocmé, Hubert Marotte, Athan Baillet, Béatrice Pallot-Prades, Jérome Garin, et al.. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis.. Annals of the Rheumatic Diseases, BMJ Publishing Group, 2009, 68 (8), pp.1328-33. ⟨10.1136/ard.2008.093153⟩. ⟨inserm-00382264⟩

Share

Metrics

Record views

739

Files downloads

1281